---
title: "Morgan Stanley lowers the target price for Ascentage to 89 yuan, reiterates \"Overweight\" rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283433538.md"
description: "JP Morgan has lowered the target price for Ascentage from 93 yuan to 89 yuan, maintaining an \"overweight\" rating. It is expected that Takeda Pharmaceutical Company will not exercise its exclusive option for orebatinib before 2027, while assuming that the chronic myeloid leukemia indication will obtain Phase III clinical trial data in 2027, with commercialization delayed until 2028. Looking ahead, orebatinib and lisaftoclax are considered potential growth drugs for the company in the medium to short term"
datetime: "2026-04-21T03:27:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283433538.md)
  - [en](https://longbridge.com/en/news/283433538.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283433538.md)
---

# Morgan Stanley lowers the target price for Ascentage to 89 yuan, reiterates "Overweight" rating

JP Morgan published a research report indicating that it has lowered the target price for ASCENTAGE-B (06855.HK) from HKD 93 to HKD 89, maintaining an "Overweight" rating.

Morgan Stanley expects that Takeda Pharmaceutical Company will not exercise its exclusive option for olverembatinib before 2027. Additionally, the firm assumes that data from the Phase III clinical trial for chronic myeloid leukemia will be obtained in 2027, delaying its commercialization to 2028.

The firm stated that looking ahead, olverembatinib and lisaftoclax are differentiated and promising drugs that could become the cornerstone of the company's growth in the medium to short term

### Related Stocks

- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)
- [06855.HK](https://longbridge.com/en/quote/06855.HK.md)
- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [AAPG.US](https://longbridge.com/en/quote/AAPG.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [AAPGV.US](https://longbridge.com/en/quote/AAPGV.US.md)

## Related News & Research

- [Most-Favored-Nation Drug Pricing to Save U.S. $529 Billion Over 10 Years, Report Suggests](https://longbridge.com/en/news/285242629.md)
- [Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML](https://longbridge.com/en/news/284156997.md)
- [Tires Easy Launches "Give for More Life (and Moments)" Campaign to Support Blood Cancer United](https://longbridge.com/en/news/285104009.md)
- [Aclarion Signs Agreement With Weill Cornell For Use Of Nociscan To Treat Lumbar Disc Disease](https://longbridge.com/en/news/285229471.md)
- [Hecla Mining Q1 revenue rises 13% on higher metals prices](https://longbridge.com/en/news/285268592.md)